Motiva (ESTA): Debts to Book Capitalization

Brandmark of Establishment Labs Corp (ESTA)

Establishment Labs relies on a team of cutting-edge engineers developing innovative women's health solutions. Revenue growth is driven by the global promotion of the Motiva brand, and the 11.30 metric confirms its current status. This price action chart below demonstrates the company's market trend. The business minimizes risks by utilizing its own assembly plants for implants, limiting external interaction solely to polymer procurement and transport services.

ESTA - Establishment Labs Inc Debts to Net Assets over the range 07/04/2022 - 10/27/2026
Original product of Establishment Labs Corp

Establishment Labs' expansion into the premium implant segment requires an assessment of financial stability by comparing all liabilities against the net asset value. By analyzing the ratio of total debt to balance sheet capital, an investor determines the extent to which business development depends on borrowed funds, where an increasing value indicates heightened financial leverage and a decrease reflects the strengthening of the company's fundamental autonomy.

Competitors of Establishment Labs

BSX: Debts to Book Capitalization|Debts to Book Value edwards.com EW|RMD: Debts to Book Capitalization|PODD - Debt to Book Value|Zimmer Biomet - Debts to Book Capitalization|CooperSurgical (COO) - Debts to Net Assets|ALGN (Align Technology, Inc.) - Debts to Book Capitalization|Debts to Book Capitalization GMED|Debt to Book Capitalization Ratio TransMedics Organ Care System (TMDX)|Debt to Book Capitalization Ratio Alphatec Holdings (ATEC)|Debts to Book Capitalization AORT|ENOV - Debts to Net Assets|Debt to Book Value Integra LifeSciences|BBNX - Debts to Book Capitalization Ratio|Debts to Book Capitalization IRMD|Embecta Corp (EMBC) - Debts to Book Value|Debts to Book Capitalization Tandem Diabetes (TNDM)|Debt to Book Value Ratio Axogen Surgical (AXGN)|SI-BONE, Inc. (SIBN) - Debt to Book Value|Debt to Net Assets Ratio OFIX (orthofix.com)|Bioventus - Debt to Book Capitalization Ratio|Debt to Book Value OrthoPediatrics Corp KIDS|TMCI (Treace Medical) - Debts to Book Capitalization|SRTA - Debts to Book Value|Debts to Book Capitalization Carlsmed Inc|rxsight.com (RXST) - Debt to Book Value Ratio|CLPT: Debts to Book Capitalization|Debts to Net Assets Stereotaxis Inc|Debts to Book Capitalization STIM (NeuroStar)|Debt to Book Value Sight Sciences Inc (SGHT)|Debts to Book Capitalization OBIO (Orchestra BioMed, Inc.)|Anika Therapeutics Inc. - Debts to Book Capitalization|NSPR - Debt to Book Capitalization Ratio|Jin Medical International (ZJYL) - Debt to Book Capitalization Ratio|Debt to Book Value vivani.com VANI|Xtant Medical (XTNT) - Debt to Net Assets Ratio|Debts to Book Capitalization NMTC (NeuroOne Medical Technologies)|Debts to Book Value MODD|MYO: Debt to Book Capitalization Ratio|Debt to Net Assets Envoy Medical Inc. COCH|Debt to Book Value VVOS (Vivos Therapeutics, Inc)|Debts to Book Capitalization enVVeno Corp NVNO|Debts to Book Capitalization SINT (SINTX Technologies)|TNON: Debts to Net Assets|Debt to Book Capitalization Ratio Lifeward (LFWD)|AMIX (Autonomix Medical) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio IVF|Debt to Book Value Bone Biologics Inc|Axonics, Inc. - Debts to Book Capitalization|Debts to Book Value BIOL (biolase.com)|DYNT - Debt to Book Capitalization Ratio|FNA - Debt to Book Value Ratio|Debt to Book Value INVO Bio INVO